Skip to main content

Table 2 Clinical characteristics of non-small cell lung cancer patients with brain metastases harboring EGFR mutations

From: Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant

Characteristics

All patients

Patients with Lung-molGPA 0–2

Patients with Lung-molGPA 2.5–4

TKI-naïve group (%)

TKI-resistant group (%)

p

TKI-naïve group (%)

TKI-resistant group (%)

p

TKI-naïve group (%)

TKI-resistant group (%)

p

All patients

207 (100)

137 (100)

 

142 (100)

57 (100)

 

65 (100)

80 (100)

 

Gender

 Female

72 (34.8)

53 (38.7)

 

45 (31.7)

21 (36.8)

 

27 (41.5)

32 (40.0)

 

 Male

135 (65.2)

84 (61.3)

0.461

97 (68.3)

36 (63.2)

0.485

38 (58.5)

48 (60.0)

0.851

Smoking

 Never

97 (46.9)

68 (49.6)

 

60 (42.3)

26 (45.6)

 

37 (56.9)

42 (52.5)

 

 Current/former

110 (53.1)

69 (50.4)

0.614

82 (57.7)

31 (54.4)

0.665

28 (43.1)

38 (47.5)

0.595

Age

 < 70

162 (78.3)

112 (81.8)

 

104 (73.2)

43 (75.4)

 

58 (89.2)

69 (86.3)

 

 ≥ 70

45 (21.7)

25 (18.2)

0.431

38 (26.8)

14 (24.6)

0.747

7 (10.8)

11 (13.7)

0.588

Histology

 Adenocarcinoma

116 (56.0)

90 (65.7)

 

78 (54.9)

34 (59.6)

 

38 (58.5)

56 (70.0)

 

 Non-adenocarcinoma

91 (44.0)

47 (34.3)

0.074

64 (45.1)

23 (40.4)

0.544

27 (41.5)

24 (30.0)

0.148

KPS

 < 70

84 (40.6)

57 (41.6)

 

70 (49.3)

36 (63.2)

 

14 (21.5)

21 (26.3)

 

 70–100

123 (59.4)

80 (58.4)

0.850

72 (50.7)

21 (36.8)

0.076

51 (78.5)

59 (73.7)

0.510

Number of BM

 1–4

124 (59.9)

84 (61.3)

 

80 (56.3)

24 (42.1)

 

44 (67.7)

60 (75.0)

 

 > 4

83 (40.1)

53 (38.7)

0.793

62 (43.7)

33 (57.9)

0.069

21 (32.3)

20 (25.0)

0.331

Extracranial metastases

 Absent

81 (39.1)

47 (34.3)

 

23 (16.2)

8 (14.0)

 

58 (89.2)

39 (48.8)

 

 Present

126 (60.9)

90 (65.7)

0.365

119 (83.8)

49 (86.0)

0.704

7 (10.8)

41 (51.2)

0.352

Primary disease control

 No

94 (45.4)

63 (46.0)

 

72 (50.7)

32 (56.1)

 

22 (33.8)

31 (38.8)

 

 Yes

113 (54.6)

74 (54.0)

0.917

70 (49.3)

25 (43.9)

0.488

43 (66.2)

49 (61.2)

0.542

  1. Abbreviations: NSCLC Non-small-cell lung cancer, BM brain metastasis, Lung-molGPA Lung Cancer Molecular Markers Graded Prognostic Assessment, TKI tyrosine kinase inhibitors, EGFR epidermal growth factor receptor, KPS Karnofsky Performance Status